Korro Bio

Korro Bio is a biotechnology company thatfocused on isthe pioneeringresearch and development of RNA editing to deliver the future of medicinetechnology. The company's proprietary platform, OPERA (Oligonucleotide Promoted Editing of RNA), harnessesis designed to use the natural base editing system of the body, specifically ADAR (Adenosine Deaminase Acting on RNA), in order to make precise, single-base edits to RNA. Korro Bio was launched to turn scientific insights into life-altering new treatments for patients.

Its platform, OPERA, has been designed to address several challenges that are facing current gene therapy and gene editing approaches, including safety and flexibility of delivery mechanisms.

Korro Bio is prioritizing therapeutic indications across tissues where safe and targeted editing of messenger RNA could provide unique benefits over other modalities in development.